Patients with schizophrenia have a lot of life-changing consequences when they are being treated properly, and these are only amplified when the patient goes untreated, explained Megan Ehret, PharmD, of University of Maryland, School of Pharmacy.
There are life-changing aspects to schizophrenia that are amplified when patients are untreated for the condition, explained Megan Ehret, PharmD, MS, BCPP, professor and codirector of the Mental Health Program, University of Maryland, School of Pharmacy.
Ehret discussed schizophrenia management strategies in a session at AMCP Nexus, held October 14-17 in Las Vegas, Nevada.
This transcript has been lightly edited for clarity.
Transcript
How does a schizophrenia diagnosis affect the day-to-day lives of patients both when they are being treated properly and when they are not?
When we think about the treatment of schizophrenia, there are life-changing consequences just to the illness itself. There is a lot more social isolation. There can be stigma and reduced aspects and quality of life. You may be less likely to have a partner, less likely to maybe accomplish college or other aspects of life.
When it goes untreated, those are just amplified. The patient may be hearing voices. They may be paranoid about things around them. Ultimately, each of those things can affect different parts of their lives. They also, additionally, have the potential with schizophrenia to have a reduced life expectancy because of some of the aspects of the illness.
When schizophrenia is appropriately treated, and we use an effective medication, people can go on to have the same quality of life as someone without schizophrenia. They are able to attend college, able to obtain employment, able to have families and function. I think Bethany's story [from the AMCP Nexus session] really highlights how when she found the most effective treatment, she was able to continue on and finish her college degree and complete the quality of life that she was looking for.
It's unfortunate many of our treatments also decrease the life expectancy, because of the adverse effects that can occur from those. So, it's important that when patients are engaged in treatment that they continue to have monitoring so that we can make sure that those things are all adequately monitored and watched for.
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More